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Urethral NTCP has been determined for three prostates implanted with seeds based on 125I (145Gy), 103Pd (125Gy), 131Cs
(115Gy), 103Pd-125I(145Gy),or 103Pd-131Cs(115Gyor130Gy).First,DU20,meaningthat20%oftheurhralvolumereceive adose
ofatleastDU20,isconvertedintoanI-125LDRequivalentDU20 inordertousetheurethralNTCPmodel.Second,thepropagation
of uncertainties through the steps in the NTCP calculation was assessed in order to identify the parameters responsible for large
data uncertainties. Two sets of radiobiological parameters were studied. The NTCP results all fall in the 19%–23% range and
are associated with large uncertainties, making the comparison diﬃcult. Depending on the dataset chosen, the ranking of NTCP
values among the six seed implants studied changes. Moreover, the large uncertainties on the ﬁtting parameters of the urethral
NTCP model result in large uncertainty on the NTCP value. In conclusion, the use of NTCP model for permanent brachytherapy
is feasible but it is essential that the uncertainties on the parameters in the model be reduced.
1.Introduction
Radiotherapy treatment planning systems incorporating
“biological” models are beginning to make their way into
clinicaluse.ThebiologicalmodelsinquestionsareforTumor
Control Probability (TCP) [3, 4]a n dN o r m a lT i s s u eC o m -
plication Probability (NTCP) [5, 6]. A common suggestion
is that treatment plans be optimized to maximize the TCP
while not exceeding a ﬁxed, acceptable NTCP [7, 8]. A con-
siderable amount of work has been done to implement this
biologicalmodel-basedapproachinpermanentseedprostate
brachytherapy[1,9–12].Prostatebrachytherapymorbidityis
generally reported for the urethra [13–17]a n dr e c t u m[ 18–
21]. Zaider et al. have extended radiotherapy NTCP models
for these organs to Low Dose Rate (LDR) permanent brachy-
therapy [1, 12].
Three radionuclides are generally used in permanent
prostate brachytherapy: iodine-125, palladium-103, and
cesium-131. Each radionuclide has its advantages but also
its drawbacks. 125Ia n d131Cs have similar emission spectrum
whose mean energies are 28.37 and 30.45keV, respectively.
103Pd has a mean emitted energy of 20.74keV which reduces
the dose to the surrounding organs at risk (OAR) such as
rectum and urethra but also increases the risk of cold spots
(underdosage) in the prostate. By contrast, the 125Ia n d131Cs
dose distributions extend to larger distances, thus reducing
the likelihood of cold spots at the cost of delivering more
to the OARs for a given prostate dose. Urethral and rectal
complications are reported at a similar frequency for 125Io r
131Cs [22].
The contrast between the properties of 103Pd, 125I, and
131Cs has motivated our research in developing a new kind
of seed based on a mixture of two radionuclides, namely,
103Pd0.75-125I0.25 or 103Pd0.25-131Cs0.75. The subscripts denote
the fractions of internal activity of each radionuclide as
deﬁned in a previous paper [23]. To avoid a cumbersome
style, the 103Pd0.75-125I0.25 and 103Pd0.25-131Cs0.75 mixture will
be referred to in the text as Pd-I and Pd-Cs. The dosimetry
characteristics and prescription doses of these sources were
d e r i v e di np r e v i o u ss t u d i e s[ 23, 24].
I no u rs t u d y ,w eu s et h eZ a i d e re ta l .N T C Pm o d e lf o r
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Table 1: Prostate and urethra volumes for each planned patient.
Patient p01 p02 p03
Prostate volume (cc) 24.64 38.9 45.33
Urethra volume (cc) 0.32 0.19 0.28
Table 2: Prescription dose for the diﬀerent seeds used for planning.
103Pd 125I 131Cs Pd-I Pd-Cs
Internal activity 100% 100% 100% 75%–25% 25%–75%
Prescription dose (Gy) 125 145 115 145 130 (a)
115 (b)
(103Pd, 125Ior131Cs)andbi-radionuclideseedimplants(Pd-I
or Pd-Cs). A sensitivity analysis on the modeling parameters
is also performed.
2. Patientsand Methods
2.1. Treatment Plans. A source data ﬁle for the Prostate
Seed Implant Dosimetry (PSID) Treatment Planning System
(TPS) has been generated for InterSource seeds loaded with
either 103Pd, 125I, 131Cs, Pd-I, or Pd-Cs following the AAPM
TG43U1 formalism, which we have adapted for multiple
radionuclide brachytherapy sources [23].
Three patients were planned using peripheral seed place-
ment: patient 1 with the smallest prostate, patient 2 with
a medium-sized prostate, and patient 3 with the largest
prostate. Prostate and urethra volumes of each patient are
given in Table 1. The urethral volume is deﬁned as the
volume enclosed by the urethra surface. Each patient has
been planned with the ﬁve types of seeds. The prescription
doses used for bi-radionuclide implants have been derived
previously [24] and are summarized in Table 2. The method
that we used yields a single, ﬁxed value of 142Gy for the
prescription dose of a Pd-I implant whereas it results in two
diﬀerent values for the Pd-Cs mixture: 115Gy and 128Gy.
However, these values are associated with large uncertainties.
They were rounded to 145Gy, 115Gy, and 130Gy, respec-
tively, as safety margins on tumor control. The total number
of treatment plans is therefore 18 (6 plans per patient).
2.2. Urethra NTCP. To the best of our knowledge, only
Zaider et al. [1] have developed a model for the urethra
NTCP after I-125 LDR. This model is based on a correlation
between the probability of urethral toxicity and the dose
received by the “hottest” 20% of the urethral volume (DU20)
after permanent prostate brachytherapy using 125I seeds. In
order to apply such a model, and because in our study we
are dealing with diﬀerent radionuclides, we have converted
the dose distribution for each implant to an equivalent I-125
LDR one. In order to do this, we derive the DU20-I of an I-
125 LDR treatment that would yield the same Biologically
Eﬀective Dose (BED) as the implant in question. The BED
includes a linear and a quadratic term in dose. In the
case of bi-radionuclide implant, its formulation requires the
Table 3: Modeling parameters and their absolute uncertainties. p is
the value of the considered parameter.
Parameter Units pp −  p+ 
γ — −2.60 −3.10 −2.10
ζ Gy 0.0066 0.0050 0.0082
μ h−1 1.0 0 1.5
α/β Gy 16.6 5 25
RBEPd — 1.41 1.00 1.75
RBEI — 1.28 1.00 1.45
RBECs — 1.28 1.00 1.45
δ1 — Variable δ1 −0.020 δ1 +0.020
contribution of each radionuclide to the DU20. The models
and procedure are described in what follows.
2.2.1. Logistic Model. Based on a logistic regression analysis
ofpatients treatedbyI-125 LDR,Zaideretal.[1] inferred the
probability of unresolved Grade 2 or higher urethral toxicity
at 12 months as a function of DU20:
NTCPureth = Ptox,12(DU20-I) =
1
1+e xp
 
−
 
γ +ζDU20-I
  ,
(1)
where γ and ζ are two ﬁtting parameters given with their
uncertainties in Table 3. Further in the text, iodine-125
referring to the I-125 LDR equivalent implant will be noted
I-125 whereas iodine-125 referring to our implants will be
noted 125I.
2.2.2. I-125 LDR Equivalent DU20. The parameters of the
urethral NTCP model correspond to an I-125 LDR treat-
ment. Hence, the DU20 for the diﬀerent other radionuclides
or mixtures has to be converted to an I-125 LDR equivalent
DU20. This conversion will be referred to below as “I-
125 conversion”. The Biologically Eﬀective Dose (BED) is
a powerful tool for this purpose as it allows a comparison
of diﬀerent treatment modalities.
The BED for an LDR implant whose seeds contain one
radionuclide is [2, 25]
BEDLDR = RBEmax · DU20 +
1
α/β
λ(DU20)
2
 
λ+μ
  ,( 2 )
where RBEmax is the Relative Biological Eﬀectiveness of the
radionuclide at very low-dose rate; [2]; α/β is the ratio
of radiosensitivity parameters; λ is the radioactive decay
constant of the radionuclide; μ is the sublethal cell damage
repair rate. For the urethra, the commonly used values for
α/β and μ are 3Gy and 0.5h−1 respectively. For normal
tissues, cell repopulation is not taken into account. The
RBEmax values used in this study are from Wang et al.
[26]: 1.41 for 103Pd and 1.28 for 125I. Due to the lack of
experimental data on the RBEmax of 131Cs, its value has
been set to the same value (i.e., 1.28) as that for 125I. This
assumption is based on the fact that their emission spectra
are similar. Note that (2)d i ﬀers from the expression inProstate Cancer 3
Zaider et al. [1] one. However, as the sublethal cell damage
repair rate for the urethra is much larger than the radioactive
decay constant, both results ﬁt within 1% in the worst case.
The clinical outcome would be equivalent for two
treatments if they yield the same BED:
BEDLDR-x = BEDLDR-I,( 3 )
RBEmax-x ·DU20-x+
1
α/β
λx(DU20-x)
2
 
λx +μ
 
= RBEmax-I ·DU20-I +
1
α/β
λI(DU20-I)
2
 
λI +μ
  .
(4)
The I-125 LDR equivalent DU20-I of the DU20-x resulting
from an implant based on radionuclide x can be calculated
by expressing (4)a saq u a d r a t i c
A[DU20-I]
2 +B ·[DU20-I]+C = 0, (5)
where
A =
λI  
λI +μ
 ,( 6 )
B =
 
α
β
 
RBEmax−I,( 7 )
C =−
  
α
β
 
RBEmax−x ·DU20−x +
λx(DU20−x)
2
 
λx +μ
 
 
. (8)
As DU20-I, A and B must have positive values, the only
valid solution of (5)i s
DU20-I =
−B +
√
B2 − 4AC
2A
. (9)
For a bi-radionuclide seed implant, the solution is the
same as (9) with same expression for A and B, but the
expression of C is
C =−
⎡
⎣
 
α
β
 
DU20
2  
i=1
δi ·RBEmax-i
+2(DU20)
2
2  
i=1
2  
j=1
λiλjδiδj
 
λi +μ
  
λi +λj
 
⎤
⎦,
(10)
where DU20 is the one of the bi-radionuclide implant and δi
is the contribution of radionuclide i in the seed to the DU20.
2.2.3. Bi-radionuclide Case: δi Contributions. Equation (10)
requires that the contribution δi of each radionuclide to
DU20 be known for each point in space that is considered.
Treatment plans show that the relative contribution of each
radionuclide can be considered as constant throughout the
urethral volume. Hence, everywhere in the urethra:
D = D1 +D2 = D(δ1 +δ2) = D(δ1 +(1 −δ1)). (11)
Let us include the RBE eﬀect directly in the TPS ﬁle that
deﬁnes the seed data (dose distribution in the adapted
AAPM TG43U1 dosimetry formalism [23]). This can be
done by modifying the adapted radial dose function and 1D-
anisotropy function of the seed (see Appendix). The dose
distribution DRBE in the organs provided by the TPS would
therefore also include the RBE eﬀect:
DRBE = D1RBEmax-1 +D2RBEmax-2,
= D(δ1RBEmax-1 +δ2RBEmax-2),
(12)
DRBE = D(δ1RBEmax-1 +(1 −δ1)RBEmax-2). (13)
As the δi’s are spatially independent, (13) can be applied
directly to the DU20 value. Therefore, if the DU20 from
the treatment plan with and without RBE eﬀect (DU20-RBE
and DU20, resp.,) are known, then the contribution of each
radionuclide to DU20 can be computed from
δ1 =
((DU20-RBE/DU20) −RBEmax-2)
(RBEmax-1 −RBEmax-2)
,
δ2 = 1 − δ1.
(14)
These values turn out to match within 1% the mean δi’s
that one would obtain at the middle of the urethra contour
on each TRUS image slice. This result is not surprising as
the urethra is approximately in the middle of the prostate
and therefore in the middle of the seed distribution. All the
seeds of the implant contribute with diﬀerent magnitudes to
urethral dose, providing a homogeneous dose distribution
throughout the urethra for each radionuclide.
2.2.4. Propagation of Uncertainty. The method described in
theabovethreesectionsincludesmanyparametersassociated
with uncertainties. The uncertainties in DU20-I come from
the radiobiological parameters (μ,α/β) and the RBEmax of
each radionuclide. These uncertainties along with those of
the NTCP ﬁtting parameters will aﬀect the urethral NTCP.
TheNTCPﬁttingparameters’uncertaintieswillnotaﬀectthe
relative NTCPs of the diﬀerent seed implants as the ﬁtting
parameters are not radionuclide dependent. By contrast,
DU20-I parameters are radionuclide dependent. Therefore,
the repercussion of the DU20-I parameters’ uncertainties on
DU20-I and the subsequent repercussion on urethral NTCP
were studied.
The DU20-I uncertainty can be expressed as follows:
DU20-I =
         
∂DU20-I
∂μ
          μ+
         
∂DU20-I
∂
 
α/β
 
          
 
α/β
 
+
       
∂DU20-I
∂δ1
       δ1
+
       
∂DU20-I
∂RBEI-125
RBEI-125 +
∂DU20-I
∂RBEI
RBE1
+
∂DU20-I
∂RBE2
RBE2
       .
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The uncertainty on RBE values contains three diﬀerent
terms: the uncertainty on I-125 RBE and on the RBE of each
radionuclide in the seed. Note that in the case of mono-
radionuclideimplants,∂DU20-I/∂RBE2 =0andδ = 0.Ifthe
implant uses 125Io r131Cs, their RBEmax value has to be the
same as the I-125 RBEmax value for consistency reasons. RBE
uncertainties are therefore correlated and the absolute value
has to be taken over the whole RBE uncertainties. Moreover,
the palladium-103 RBE is correlated to the iodine-125 RBE.
Depending on the study [26, 27], if a high value of iodine-
125 RBEmax (1.45 instead of 1.28) is chosen then a high value
of palladium-103 RBEmax is obtained (1.75 instead of 1.41).
As a result, the uncertainties on 103Pd RBE are correlated to
the uncertainties on iodine-125 RBE, which can be rewritten
as
RBEPd =RBEI
 
dRBEPd
dRBEI
 
. (16)
The term into bracket has been calculated using the above
mentioned value of 103Pd and 125IRBE max valuesand is equal
to 1.65.
The NTCP uncertainty expression includes only three
terms:
NTCP =
         
∂NTCP
∂γ
          γ +
         
∂NTCP
∂ζ
          ζ
+
       
∂NTCP
∂DU20-I
        DU20-I.
(17)
The partial derivatives of DU20-I and NTCP are given in
Appendices B and C,r e s p e c t i v e l y .
3. Results
3.1. Modeling Parameters and Associated Uncertainties. The
radiobiological parameters used in this study are limited to
the α/β ratio and sublethal cell damage repair rate, μ. First,
we choose the values that Zaider et al. used in their study.
T h e s ea r et h eo n er e p o r t e di nTable 3. This high α/β ratio
is typical for tumors (typical range 5–25Gy) but does not
correspond to the commonly used value for late responding
normal tissue (typical range 1–5Gy) [2]. Therefore, we also
calculatetheDU20-I andNTCPwithα/β = 3Gy(1–5Gy)and
μ = 0.5h −1 (0–1.5h−1) reported in the Dale and Jones text
book [2]. The values into brackets are the uncertainty range
used for the uncertainty calculations.
Relative Biological Eﬀectiveness values are the one pub-
lished by Wang et al. [26]. Due to the lack of experimental
dataontheRBEmax of 131Cs,itsvaluehasbeensettothesame
value as the one of 125I. The uncertainty interval is based
on RBE values published by other authors. The minimum
RBEmax value is 1 by deﬁnition. The maximum RBEmax
values have been set to the ones published by Antipas et al.
[27].
Finally,theuncertaintyonδ1,thecontributionoftheﬁrst
radionuclide to the DU20, is equal to the maximal deviation
with respect to the mean value of the δ1 obtained in the
middle of the urethra on TRUS slices.
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Figure 1: DU20 for the diﬀerent seeds (mono- and bi-radionuclide)
and patients. The DU20 averaged over the three patients is also
plotted.
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Figure 2: I-125 LDR equivalent DU20-I results for the diﬀerent
implants (mono- and bi-radionuclide) and patients. The mean
DU20-I over the three patients is also plotted. Zaider et al. radiobio-
logical parameters are used. Error bars were calculated using (15).
3.2. DU20 and I-125 LDR Equivalent DU20 , DU20-I . The
TPSDU20 output forthe diﬀerent patients and radionuclides
are presented in Figure 1.
The mean DU20 value is also shown. As discussed above,
these values are not comparable as they do not correspond to
the same delivery scheme. Nevertheless, it will be interesting
to observe how much the DU20 is modiﬁed for each seed
implant after the I-125 conversion. It is emphasized that
the DU20 does not change signiﬁcantly from one patient to
another one.
The implants can be compared after the I-125 conver-
sion. The DU20 of each seed implant has been converted to
an I-125 LDR equivalent DU20 using (6)t o( 10)a n d( 14).
Figure 2 shows the results and the numerical values are
reported in Table 4.
The eﬀect of this conversion is to increase the DU20.
T h es m a l l e s ti n c r e a s ei so b s e r v e df o rt h e131Cs implant with
3.3Gy and the largest one for the 103Pd seed implant withProstate Cancer 5
Table 4: Dose received by the hottest 20% of the urethra
volume (DU20), 125I LDR equivalent DU20 (DU20-I), and urethra
Normal Tissue Complication Probability (NTCP) for the diﬀerent
seed implants. The values are averaged over the three patients.
Radiobiological parameters from Zaider et al. are used.
DU20 (Gy) DU20-I (Gy) NTCP (%)
125I 202.3 202.3 22.0
Pd-I 201.8 207.4 22.6
103Pd 176.3 195.8 21.3
Pd-Cs (a) 185.5 194.9 21.2
Pd-Cs (b) 169.0 177.3 19.3
131Cs 168.4 171.7 18.7
19.5Gy. The uncertainty associated with these values will
be the subject of a separate point. As expected, 125Ii sn o t
aﬀected by the I-125 conversion. The 131Cs implant is also
not signiﬁcantly aﬀected by the I-125 conversion which
suggests that the quadratic contribution of BED is small.
3.3. Urethral NTCP. Although the DU20-I ﬁgures correspond
to the same delivery scheme (I-125 LDR) and they can be
used to compare treatments, they do not give information
about the probability of urethral complications. These
probabilities have been computed using (1) and are plotted
in Figure 3. Numerical values are reported in Table 4.
TheNTCPsarelargerthantheonepublishedbyZaideret
al. who obtained NTCPs of about 16% for 143Gy I-125 LDR
[1] .H o w e v e r ,am o r er e c e n ts t u d yb yZ e l e f s k ye ta l .r e p o r t s
19% of patient experiencing late Grade 2 urinary symptoms
[28].
All the NTCP results fall in the 19 to 23% range. The
comparison between these data is therefore very diﬃcult as
these results are aﬀected by large uncertainties. Their origin
is discussed in the next section.
3.4. Uncertainties. We have calculated the contribution of
each parameters uncertainty to the total DU20-I and NTCP
uncertainties. The values are tabulated in Tables 5 and 6,
respectively.
Firstly, the results show that the DU20-I uncertainty is
mainly due to the uncertainty on the RBEmax value. The
uncertainty is the greatest for 103Pd and the least for 131Cs
apart from 125I which is not aﬀected by the conversion and
is not subjected to model-related errors. Sublethal damage
repair rate, μ,a sw e l la sr a t i oα/β have little eﬀect on the
DU20-I value.
Secondly, the urethral NTCP uncertainties are mainly
related to the parameter-ﬁtting uncertainties. The error
produced by DU20-I has a secondary importance. The total
relative uncertainty is therefore almost constant among the
diﬀerent modalities, ranging from 12 to 17%.
However, these ﬁgures also depend on the radiobio-
logical data chosen for the calculations. If the Dale and
Jones radiobiological parameters (α/β and μ) are used, the
uncertainty generated by the sublethal damage repair rate
becomes the most important one. The DU20-I and urethral
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Figure 3: Urethral NTCP results for each patient and each implant
(mono- and bi-radionuclide). The mean NTCP over the three
patientsisalsoplottedforeachimplant.Zaideretal.radiobiological
parameters are used. Error bars were calculated using (17).
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Figure 4:ComparisonofDU20−I fortwodiﬀerentvaluesofα/β and
μ : α/β = 16.6Gyandμ = 1h −1 (Zaider et al. [1]) and α/β = 3Gy
and μ = 0.5h −1 (Dale and Jones [2]). Error bars were calculated
using (15).
NTCP obtained with Zaider et al. and Dale and Jones
radiobiological parameters are compared in Figures 4 and 5,
respectively.
131Cs is the most aﬀected radionuclide. RBE uncertainty
remains almost unchanged. Uncertainties produced by δi
contributions are still negligible compared to other param-
eter’s uncertainties. These errors will have repercussions
on NTCP uncertainties with the largest eﬀect for 131Cs.
The contribution of the total DU20-I on the NTCP total
uncertaintyisnow ofthesameorderofmagnitude astheone
produced by the parameter-ﬁtting error.
4. Discussion and Conclusions
The variation in the DU20 due to I-125 conversion is
inﬂuenced by two major contributions. First, the linear term
in the BED expression depends only on the RBEmax value.
Second,thequadratictermismorecomplexandresultsfrom6 Prostate Cancer
Table 5: DU20-I uncertainty produced by each parameter and total DU20-I uncertainty for each implant using Zaider et al. radiobiological
parameters.
 DU20-I (Gy) 125I Pd-I 103Pd Pd-Cs (a) Pd-Cs (b) 131Cs
μ +  0.0 0.1 0.8 1.6 1.3 1.6
−  0.0 0.3 1.6 3.1 2.6 3.3
α/β +  0.0 0.1 0.8 1.6 1.3 1.7
−  0.0 0.2 1.1 2.2 1.8 2.3
δ1
+  0.0 0.4 0.0 0.3 0.3 0.0
−  0.0 0.4 0.0 0.3 0.3 0.0
RBE (tot) +  0.0 5.6 19.3 7.1 6.4 0.4
−  0.0 7.2 24.8 9.3 8.3 0.7
Total +  0.0 6.3 20.9 10.6 9.3 3.7
−  0.0 8.1 27.5 14.9 13.0 6.3
Table 6: NTCP uncertainty produced by each parameter and total NTCP uncertainty for each implant using Zaider et al. radiobiological
parameters.
NTCP (%) 125I Pd-I 103Pd Pd-Cs (a) Pd-Cs (b) 131Cs
γ ±  8.6% 8.7% 8.4% 8.4% 7.8% 7.6%
ζ ±  5.6% 5.8% 5.2% 5.2% 4.4% 4.2%
DU20-I
+  0.0% 0.7% 2.3% 1.2% 1.0% 0.4%
−  0.0% 0.9% 3.0% 1.6% 1.3% 0.6%
Total +  14.1% 15.3% 15.9% 14.7% 13.2% 12.2%
−  14.1% 15.5% 16.7% 15.2% 13.6% 12.4%
125I Pd-I 103Pd 131Cs
Dale and Jones
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Figure 5: Comparison of urethral NTCP for two diﬀerent values of
α/β and μ : α/β = 16.6Gyandμ = 1h −1 (Zaider et al. [1]) and
α/β = 3Gyandμ = 0.5h −1 (Dale and Jones [2] ) .E r r o rb a r sw e r e
calculated using (17).
the inﬂuence of three separate parameters: α/β and μ which
are tissue dependent and the radionuclide half-life.
Firstly, the 125ID U 20 will not be aﬀected by the I-125
conversion as only one radionuclide is involved. Secondly,
as one chooses the same RBEmax value for 131Cs and 125I,
the linear term of the 131Cs BED is not aﬀected by the 125I
conversion. Since the value of α/β chosen by Zaider et al.
is large, the quadratic contribution to the BED is small and
inﬂuences the 131Cs BED by only 2%. If future experiments
provide a RBEmax value for 131Cs that is diﬀerent from that
of 125I, larger variation in I-125 equivalent DU20 may be
observed. Thirdly, 103Pd has a larger RBEmax value than 125I.
Its linear contribution to BED will therefore also contribute
to a modiﬁed value of the DU20. This contribution of the
quadratic term accounts for only 1% of the total BED.
The diﬀerence in RBEmax value between 103Pd and I-125 is
therefore the main cause of the large increase in DU20 after
I-125 conversion. Finally, the changes in the Pd-I and Pd-Cs
DU20 due to I-125 conversion are related to both the linear
and the quadratic contribution of each radionuclide to BED.
Pd-Cs is the most aﬀected mixture as both radionuclides
diﬀer from the one used for modeling (I-125).
The very similar values obtained for the NTCP and
their large uncertainties makes it diﬃcult, if not impos-
sible, to conclude deﬁnitively whether, for equal tumour
eﬀect, bi-radionuclide brachytherapy would reduce the ure-
thralcomplicationprobabilityrelativetomono-radionuclide
brachytherapy. Planning more patients would not improve
the situation as these uncertainties are mainly due to the
ﬁtting parameter uncertainties of the empirical model of
Zaider et al.
The large value assumed by Zaider et al. for the α/β ratio
reduces the inﬂuence of the quadratic term on the total
BED considerably. Therefore the sublethal damage repair μ
on the BED will show its eﬀect only for radionuclides with
short half-lives (like 131Cs). This is also proven by the lowProstate Cancer 7
DU20-I uncertainty associated with μ and to the α/β ratio.
The uncertainty related to the δ1 also indicates that our
approximation will not signiﬁcantly aﬀect the ﬁnal results.
However, the Zaider et al. radiobiological parameters are
not the only ones in common use. The results obtained with
the radiobiological parameters from Dale and Jones (Figures
4 and 5) clearly show that such parameters could also have
a large impact on the ﬁnal NTCP value. Moreover, the
lower value of α/β ratio increases the quadratic contribution
of the BED, leading to larger uncertainties associated with
α/β and μ.
Finally, complication probabilities are certainly depen-
dent on the way the treatment planning is performed.
A logistic regression among patients treated by the each
institution could also provide diﬀerent NTCP parameter
values. However, this would not aﬀect the DU20-I results.
We can conclude that the use of the urethra NTCP model
for biologically based treatment planning in permanent seed
prostate brachytherapy requires either better ﬁtting parame-
ters (with less associated errors) or a diﬀerent NTCP model
(diﬀerent morbidity indicator than DU20 e.g.).
Appendix
A. Inclusionof RBE inTPS Dose Distribution
In order to include the RBE eﬀect in the TPS dose distribu-
tion, the radial dose function and the 1D or 2D anisotropy
functions have to be modiﬁed. This modiﬁcation is trivial
in the case of mono-radionuclide brachytherapy: the radial
dose function is multiplied by the radionuclide RBEmax value
and the anisotropy functions are not altered. In the case of
bi-radionuclide implants, the RBEmax v a l u ew i l lb ed i ﬀerent
from one radionuclide to another. Therefore,
gRBE(r) =
2  
i=1
ciRBEmax-igi(r),
φan-RBE(r) =
 2
i=1ciRBEmax-igi(r)φan-i(r)
 2
i=1ciRBEmax-igi(r)
,
F(r,θ) =
 2
i=1ciRBEmax-igi(r)Fi(r,θ)
 2
i=i ciRBEmax-igi(r)
.
(A.1)
It can be shown that if (A.1)r e p l a c e s( 11), (14)a n d( 16)
in (4)o r( 5)o fN u t t e n sa n dL u c a s[ 23], this would give
D(r,θ) =
2  
i=1
RBEmax-iDi(r,θ),( A . 2 )
which means that the TPS dose distribution includes well the
RBE eﬀect.
B. Partial Derivatives of DU20-I
DU20-I is expressed as a function of A, B,a n dC ((6)t o
(10)). Its derivative with respect to parameter p can also be
expressed as a function of A, B,a n dC and their derivative
with respect to parameter p noted (dA/dp) = ˙ A,( dB/dp) =
˙ B and (dC/dp) = ˙ C
dDU20-I
dp
=
1
2A
 
− ˙ B +
B ˙ B −2 ˙ AC −2A ˙ C
√
B2 −4AC
 
−
−B +
√
B2 −4AC
2A2
˙ A.
(B.1)
Theexpressionsof ˙ A, ˙ B,and ˙ C arenowgivenforeachparam-
eter p.
(1) p = μ,
˙ A =
dA
dμ
=
−λI
 
λI +μ
 2 =
−A2
λI
,
˙ B =
dB
dμ
= 0,
˙ C =
dC
dμ
= 2
2  
i,j=1
λiλjδiδjDU2
20−x
 
λi +μ
 2 
λi +λj
 ,
(B.2)
(2) p = (α/β),
˙ A =
dA
d
 
α/β
  = 0,
˙ B =
dB
d
 
α/β
  = RBEI-125,
˙ C =
dC
d
 
α/β
  =− DU20−x
2  
i=1
RBEiδi,
(B.3)
(3) p = RBEI-125,
˙ A =
dA
dRBEI-125
= 0,
˙ B =
dB
dRBEI-125
=
α
β
,
˙ C =
dC
dRBEI-125
= 0,
(B.4)
(4) p = RBEi,
˙ A =
dA
dRBEi
= 0,
˙ B =
dB
dRBEi
= 0,
˙ C =
dC
dRBEi
=−
 
α
β
 
DU20-xδi,
(B.5)
(5) p = δ1,8 Prostate Cancer
These expressions apply only for the bi-radionuclide implant
for which δ1 / =1
˙ A =
dA
dδ1
= 0, (B.6)
˙ B =
dB
dδ1
= 0, (B.7)
˙ C =
dC
dδ1
=−
 
α
β
 
DU20−x(RBE1 −RBE2)
−2DU2
20−x
 
λ1δ1  
λ1 +μ
  +
λ1λ2(1 −2δ1)
 
λ1 +μ
 
(λ1 +λ2)
+
λ1λ2(1 −2δ1)
 
λ2 +μ
 
(λ1 +λ2)
+
λ2(δ1 −1)
 
λ2 +μ
 
 
.
(B.8)
C. Partial Derivatives of NTCP
The NTCP expression is given by (1) and its partial deriva-
tives with respect to each parameter are
∂NTCP
∂γ
=
exp
 
−
 
γ +ζDU20-I
  
 
1+e xp
 
−
 
γ +ζDU20-I
   2,
∂NTCP
∂ζ
=
DU20-Iexp
 
−
 
γ +ζDU20-I
  
 
1+e x p
 
−
 
γ +ζDU20-I
   2,
∂NTCP
∂DU20-I
=
ζ exp
 
−
 
γ +ζDU20-I
  
 
1+e xp
 
−
 
γ +ζDU20-I
   2.
(C.1)
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